Abstract
A rapid, sensitive and simple method was developed for the quantitation of the plasma concentration of N 4-[2,6-dimethoxy-4-methyl-5-[(3-trifluoromethyl)phenoxy] -8-quinolinyl]-1,4-pentanediamine, a new antimalarial active against Plasmodium vivax. N 4-(5-Hexoxy-6-methoxy-4-methyl-8-quinolinyl)-1,4-pentanediamine diphosphate, a similar 8-aminoquinoline, was used as an internal standard. The method involves sample clean-up by a prepacked cyano solid-phase column followed by reversed-phase liquid chromatography and oxidative electrochemical detection at +0.95 V. The assay has been validated to 5 ng/ml of plasma and is sensitive to 1 ng/ml of plasma. The results of a pilot study assessing the relative oral bioavailability of two different salt forms of the new antimalarial in dogs show the usefulness of the method for animal and human pharmacokinetic studies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Journal of Chromatography B: Biomedical Sciences and Applications
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.